Teva Pharmaceutical Industries Limited (LON:0LER)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 29.76B +110.8% |
| Revenue (ttm) | 13.14B +4.4% |
| Net Income | 1.19B |
| EPS | 1.01 |
| Shares Out | n/a |
| PE Ratio | 25.11 |
| Forward PE | 15.46 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 23,930 |
| Open | 33.00 |
| Previous Close | 33.93 |
| Day's Range | 33.86 - 34.96 |
| 52-Week Range | 14.99 - 37.30 |
| Beta | 0.85 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 29, 2026 |
About LON:0LER
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
News
Teva Presents Positive Data For AUSTEDO And AUSTEDO XR In Treating Tardive Dyskinesia
(RTTNews) - Teva Pharmaceutical Industries Limited (TEVA), a pharmaceuticals company, on Friday announced new IMPACT-TD and RIM-TD data evaluating AUSTEDO and AUSTEDO XR in treating Tardive dyskinesia...
Teva presents positive long-term study data for Austedo
Teva (TEVA) announced new data highlighting symptom improvement from treatment with Austedo and Austedo XR in patients with tardive dyskinesia. Findings from the real-world IMPACT-TD study evaluated p...
Teva's Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care
PARSIPPANY, N.J. and TEL AVIV, Israel, June 08, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data t...
Teva Pharmaceutical Industries Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Management outlined a disciplined growth strategy centered on innovation, generics expansion, and capital allocation, with major product launches and pipeline readouts expected through 2028. The company’s transformation into a biopharma leader is reinforced by robust execution, undervalued assets, and a strong outlook for long-term value creation.
Teva Reports Positive Real-World Data For AUSTEDO And AUSTEDO XR In Treating Huntington's Chorea
(RTTNews) - Teva Pharmaceutical Industries Limited (TEVA), a pharmaceuticals company, on Friday announced new data from the real-world study evaluating AUSTEDO and AUSTEDO XR in treating Huntington's ...
TEVA Unveils Positive Results in Real-World Study of AUSTEDO for Huntington's Disease
TEVA Unveils Positive Results in Real-World Study of AUSTEDO for Huntington's Disease
3 Generic Drug Stocks to Watch as New Growth Drivers Emerge
Sandoz, Teva and Viatris target biosimilars, complex generics and specialty drugs as new growth drivers reshape the Medical - Generic Drugs industry.
Teva announces new data on AUSTEDO tablets, AUSTEDO XR tablets
Teva (TEVA) Pharmaceuticals announced new data from the first and only real-world, decentralized study evaluating the patient- and caregiver-reported quality of life impacts of Huntington’s disease ch...
Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington’s Disease Chorea
New real-world survey data reveal the daily impact of Huntington’s disease (HD) chorea, with over 68% of patients reporting interference with social life or emotional wellbeing1 and up to 83% of careg...
Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea
PARSIPPANY, N.J. and TEL AVIV, Israel, June 05, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data f...
Teva (TEVA) Launches New Biosimilar Ahzantive in Europe
Teva (TEVA) Launches New Biosimilar Ahzantive in Europe
Teva launches Ahzantive in Europe
Teva (TEVA) announced the launch of Ahzantive, a biosimilar to Eylea, in Europe. The launch of Ahzantive pre-filled syringes began in May across several European markets, including France, Germany, Sp...
Alvotech And Teva Resubmit BLAs To FDA For Biosimilars AVT05 And AVT06
(RTTNews) - Alvotech (ALVO), a biotechnology company, on Thursday announced the re-submission of the Biologics License Applications (BLAs) for biosimilars ATV05 and ATV06 to the U.S. Food and Drug Adm...
Teva Pharmaceutical Industries Ltd (TEVA) Stock Down 4.5% but Still Overvalued -- GF Score: 55/100
Teva Pharmaceutical Industries Ltd (TEVA) Stock Down 4.5% but Still Overvalued -- GF Score: 55/100
UroGen Pharma (URGN) Settles Patent Dispute with Teva Pharmaceuticals (TEVA)
UroGen Pharma (URGN) Settles Patent Dispute with Teva Pharmaceuticals (TEVA)
Teva to Present at the Goldman Sachs Global Healthcare Conference
PARSIPPANY, N.J., and TEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will...
Teva Pharmaceutical Industries Just Pulled Off One of Pharma's Most Impressive Comebacks
Thanks to its pivot from generic to branded drug products, Teva Pharmaceutical Industries has experienced a dramatic price rebound. Even after surging 90% higher over the past year, Teva's comeback ma...
TEVA Partners with Veeva Systems for Global CRM Implementation
TEVA Partners with Veeva Systems for Global CRM Implementation
Teva commits to Veeva Vault CRM
Veeva Systems (VEEV) announced that Teva Pharmaceuticals (TEVA) has committed to Veeva Vault CRM globally. “We are excited to expand our strategic partnership with Veeva by moving to Vault CRM,”…
Teva: European Medicines Agency Accepts Marketing Authorization Application For TEV-'749
(RTTNews) - Teva Pharmaceuticals International GmbH, a unit of Teva Pharmaceutical Industries (TEVA), and Medincell announced that the European Medicines Agency has accepted the Marketing Authorizatio...
TEVA Gains EMA Acceptance for New Schizophrenia Treatment
TEVA Gains EMA Acceptance for New Schizophrenia Treatment
Teva announces EMA acceptance of MAA for olanzapine long-acting injectable
Teva (TEVA) Pharmaceuticals International announced that the European Medicines Agency has accepted the Marketing Authorization Application for olanzapine long-acting injectable for the treatment of s...
The European Medicines Agency Accepts Teva's Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults
TEL AVIV, Israel and PARIS, May 21, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and Medincell (Euronext...
Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution
TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's corporate cred...
Teva Reports Gap In Tardive Dyskinesia Diagnosis Among Patients With Mood Disorders
(RTTNews) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA) on Monday announced new real-world data from the IMPACT-TD Registry showing a significant gap in diagno...